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In Brief Sulahian, Kwon, and Walsh et al. performed several loss-of-function CRISPR-Cas9 screens in KRAS-mutant cancer cells treated with a MEK inhibitor and define the landscape of modifiers of MEK inhibitor sensitivity while highlighting that SHOC2 is a potent synthetic lethal target that serves as a critical signaling node to mediate MAP kinase pathway reactivation upon MEK inhibition.
INTRODUCTION
KRAS is a major oncogenic driver in a variety of tumor types, including pancreatic ductal adenocarcinoma, lung adenocarcinoma, and colorectal carcinoma. The KRAS protein itself has been challenging to target with small molecule inhibitors (Simanshu et al., 2017; Stephen et al., 2014) . The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway is activated by oncogenic RAS signaling to promote cancer cell proliferation and survival (Aguirre and Hahn, 2018; Papke and Der, 2017) . Although potent inhibitors have been developed for MEK1/2 and ERK1/2 in the MAPK pathway, single-agent efficacy of these inhibitors in the clinic has been limited (Aguirre and Hahn, 2018; Blumenschein et al., 2015; Chapman et al., 2014; Infante et al., 2012; Jä nne et al., 2013) . Major modes of intrinsic and acquired resistance to MEK or BRAF inhibitor monotherapy in RAS-or BRAF mutant cancers include the loss of feedback inhibition and upregulated RTK signaling (Corcoran et al., 2012; Duncan et al., 2012; Nazarian et al., 2010; Villanueva et al., 2010) ; NF1 inactivation (Whittaker et al., 2013) ; or increased NRAS (Nazarian et al., 2010) , A/B/C-RAF (Das Thakur et al., 2013; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2011; Villanueva et al., 2010) , COT (Johannessen et al., 2010) , or MEK1/2 activity (Nikolaev et al., 2011; Wagle et al., 2011) . These studies highlight a key role for sustained RTK/MAPK signaling in mediating resistance to inhibition of this pathway in RAS-or BRAF mutant cancers.
An alternative strategy for directly targeting KRAS itself involves identifying co-dependent signaling pathways that are essential for cancer survival in the context of therapeutic inhibition of KRAS effector signaling pathways. Elucidating these synthetic lethal interactions will inform our understanding of KRAS biology and may provide additional opportunities for combination therapeutic development to treat KRAS-mutated cancers. Over the past several years, multiple groups have used RNAinterference screening with small molecule inhibition of oncogenic signaling pathways in RAS mutant cancers to identify several synthetic lethal targets for combination therapy, including BCL-XL (Corcoran et al., 2013) , PTPN11 (Prahallad et al., 2015) , YAP1 , ERBB3 , and FGFR1 (Manchado et al., 2016) . Moreover, recent CRISPR-Cas9 screens utilizing single guide RNA (sgRNA) libraries targeting the ''druggable'' genome have nominated additional synthetic lethal targets for combination with MEK inhibition, such as MAPK7 (Dompe et al., 2018) and SRC (Anderson et al., 2017) . We have also recently employed genome-scale CRISPR-Cas9 screening in the context of MEK inhibition to identify mediators of resistance to MAPK inhibition, including the ATXN1L-CIC-ETS axis and the KEAP1/NRF2 pathway (Krall et al., 2017; Wang et al., 2017a) . SHOC2 is a scaffold protein composed of leucine-rich repeats and is a positive regulator of the RAS-MAPK pathway (Simanshu et al., 2017) . SHOC2 binds directly to MRAS and the catalytic subunit of PP1 (PP1c) leading to membrane localization and dephosphorylation of c-RAF at S259 to cause c-RAF activation (Rodriguez-Viciana et al., 2006; Simanshu et al., 2017) . Activating mutations in SHOC2, MRAS, and PP1c are found in Noonan-like syndrome, a ''RASopathy'' syndrome characterized by congenital cardiac, skeletal, and cognitive deficits (Cordeddu et al., 2009; Gripp et al., 2016; Higgins et al., 2017; Young and Rodriguez-Viciana, 2018) . Recent CRISPR-Cas9 screening data have shown that SHOC2 is essential for proliferation of RAS mutant leukemia lines but not RAS wild-type lines (Wang et al., 2017b) .
Here, we performed genome-scale CRISPR-Cas9 loss-offunction screens in the setting of MEK inhibition (MEKi) to define the landscape of synthetic lethal interactors with MEKi. We provide a systematic view of modifiers of MEK inhibitor sensitivity and nominate multiple combination therapy targets. We found that additional perturbation of the RTK-RAS-MAPK pathway strongly cooperated with MEKi to inhibit proliferation and survival of RAS-driven cancer cells. In particular, we identified SHOC2 as a key regulator of KRAS mutant cancer cell proliferation and survival in the setting of MEKi.
RESULTS

Loss-of-Function Genetic Screens to Identify Modifiers of MEK Inhibitor Sensitivity
To identify modifiers of sensitivity to small molecule inhibition of the MAPK signaling pathway, we performed pooled genomescale CRISPR-Cas9 screens in established KRAS-mutant pancreatic or lung cancer cell lines in the presence or absence of the MEK1/2 inhibitor trametinib (Gilmartin et al., 2011) (CRISPR-MEKi screens; Figure 1A ). Using phosphorylated ERK (p-ERK) as a biomarker to assess the effectiveness of MEK inhibition, we identified a trametinib drug concentration that achieved pathway inhibition while still allowing cell proliferation to enable identification of negatively selected sgRNAs in these screens (Figures S1A-S1C). We introduced a genome-scale CRISPR-Cas9 sgRNA library (Doench et al., 2014) in three KRAS mutant cancer cell lines-CFPAC-1, A549, and NCI-H23-and subsequently identified the differential abundance of sgRNAs in trametinib-treated or dimethyl sulfoxide (DMSO) control-treated cells after 14 days of treatment ( Figure 1A ; Table S1 ; STAR Methods).
To identify genes whose depletion modified the response to MEKi, we averaged the measured abundance of guides targeting each gene to calculate gene-level scores. Specifically, we calculated a ''trametinib sensitivity score'' and a ''DMSO sensitivity score'' reflecting the mean log2-fold change between the endpoint (14 days in trametinib or control) and initial library representation for all sgRNAs targeting each gene in the trametinib and control arms of the screen, respectively (STAR Methods). We then compared the trametinib-treated arm with the control DMSO-treated arm of each screen to yield a ''differential sensitivity score,'' reflecting the preferential dependence of each gene in the presence of trametinib. We prioritized candidates that showed enhanced depletion in the context of MEK inhibition and that were also strongly depleted in the trametinib arm of the screen, thus displaying highly negative differential sensitivity scores and trametinib sensitivity scores ( Figures 1B-1D ; Table S2 ). The genes targeted by these sgRNAs represented potential synthetic lethal interactors that, when depleted, cooperated with MEK inhibition in KRAS mutant cancer cells.
To examine the major mechanisms of sensitization to MEK inhibition across cell lines, we performed an integrative analysis of the genome-scale CRISPR-MEKi screens in CFPAC-1, A549, and NCI-H23. Using the STARS algorithm (STAR Methods) (Doench et al., 2016) , we identified genes with statistically significant differential sensitivity scores reflecting differences between trametinib and control-treated arms of the screen. With a false discovery rate (FDR) threshold of % 0.25, we identified a total of 184 genes that exhibited preferential essentiality with MEK inhibition in one or more cell lines. Confirming the robustness of our CRISPR-MEKi screens, several genes previously identified as synthetic lethal interactors with MEKi scored in these screens including BCL2L1 (Corcoran et al., 2013) , RAF1 (Lito et al., 2014) , and PTPN11 (Prahallad et al., 2015) 
We observed considerable gene-level heterogeneity across cell lines, with only 18 genes scoring in two or more lines and 4 genes observed in all three cell lines ( Figure 1E ). Both biological and technical features may contribute to this heterogeneity, including variation in underlying genetic and lineage characteristics of each cell line (Table S1 ), differential baseline essentiality of some of these cancer-relevant dependencies in the untreated state (Figures S1D-S1F). Despite variation in differential sensitivity at the gene level, examination of these synthetic lethal candidates using knowledge of known pathways indicated strong and consistent convergence on RTK-RAS-MAPK signaling (F-H) Representative secondary screens performed with a focused CRISPR-Cas9 library in MIA PaCa-2 (F), NCI-H2009 (G), and Panc 10.05 (H). Red points, FDR < 0.25. (I) Circos plot showing genes recurrently scoring as MEKi sensitizers across one or more of 10 different genome-scale (n = 3) and secondary-focused (n = 7) CRISPR-MEKi screens, with criteria for inclusion: (1) STARS FDR % 0.25 for the trametinib versus Control comparison and (2) a trametinib sensitivity score of % À0.5. Each arc represents a gene list. On the inner arc, dark orange color represents genes that appear in multiple lists and light orange color represents genes that are unique to that gene list. Purple lines link genes shared by multiple lists. (J) Summary of all screens (genome scale and secondary), plotting the combined average of the mean differential sensitivity score (y axis) and the mean trametinib sensitivity score (x axis) across all lines screened. The size of the point is proportional to the number of times each gene scored in a screen with a differential sensitivity score having an FDR < 0.25. The metascape suite of tools (http://metascape.org) was used to analyze gene targets scoring as sensitizers to the trametinib in 10 CRISPR-MEKi screens. Genes were included in the analysis if they scored with a differential sensitivity score having an FDR % 0.25 by the STARS algorithm and a trametinib sensitivity score of % À0.5 in one or more screens. (A) Pathway enrichment of genes scoring in two or more screens within the MSigDB canonical pathways database. (B) Top 20 enriched canonical pathways among cell lines screened.
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(C) Protein-protein interaction meta-analysis. Input gene lists from all 10 CRISPR-MEKi screens were merged into one list and resulted in a single PPI network representing the full interactome (center network). Each MCODE component in the merged network is assigned a unique color and has been separated out and aligned radially around the full interactome. MCODE networks are labeled by representative members and displayed with nodes as pie charts. The color code for each pie sector represents a gene list from each CRISPR-MEKi screen, thus demonstrating which of the genes in the networks scored in each of the pathways, with different members of these pathways (e.g., FGFR1 and RAF1) observed in all three screens (Figures S1G-S1J) (Tripathi et al., 2015) . Although our CRISPR-MEKi screens were designed as negative-selection screens, we also identified several genes whose depletion led to decreased sensitivity or resistance to MEK inhibition ( Figures 1B-1D and S1K-S1N; Table S3 ). Using an FDR threshold of % 0.25, we found a total of 614 unique genes in the three cell lines but only 58 genes observed as resistance factors in two or more screens, reminiscent of the heterogeneity that we observed for genes that synergize with MEKi. Within the compendium of resistance genes, we identified several tumor suppressor genes that activate PI3K-AKT-MTOR signaling, including PTEN, TSC1, and TSC2 (Table S3 ). We also identified genes encoding the negative regulators of the RAS-MAPK pathway, including DUSP6 and the GTPase-activating protein RASA2. Moreover, we identified several genes whose products regulate oncogenic transcription, such as the aryl hydrocarbon receptor (AHR) or regulators of the ATXN1L-CIC-ETS transcription factor axis (e.g., RFWD2 and DET1), which we had previously identified in a CRISPR-MEKi screen in the PA-TU-8988T pancreatic cancer cell line (Wang et al., 2017a) .
To extend and validate the observations from these CRISPR-MEKi screens, we developed a focused secondary screening CRISPR-Cas9 sgRNA library to interrogate the top-scoring genes in a panel of KRAS mutant cancer cell lines. Using an all-in-one vector system encoding both Cas9 and an sgRNA, we created a library of 4831 reagents targeting control and experimental genes, including 527 synthetic lethal candidate genes that were nominated according to their differential sensitivity scores by the STARS algorithm (Doench et al., 2016) (Table S4 ; STAR Methods). We screened seven additional KRAS mutant cancer cell lines, including four pancreatic cancer lines and three lung cancer cell lines ( Figures 1F-1H ). Thus, a total of ten CRISPR-MEKi screens were performed using either the genome-scale or focused secondary screening sgRNA libraries ( Figure 1I ; Table S1 ).
To evaluate the landscape of recurrent MEKi synthetic lethal candidate genes, we performed an integrative analysis of all primary genome-scale and secondary CRISPR-MEKi screens (n = 10 screens), prioritizing genes by (1) the most negative average differential sensitivity score and trametinib sensitivity score in all ten lines and (2) the number of cell lines in which each gene scored as a synthetic lethal candidate ( Figure 1J ). SHOC2 was the most recurrent and strongest scoring synthetic lethal dependency in the presence of MEK inhibition across all ten screens analyzed ( Figure 1J ).
RTK-RAS-MAPK Pathway Components Are Synthetic Lethal Interactors with MEK Inhibition
To understand common pathways and interactions among synthetic lethal candidates, we performed a meta-analysis of pathway and protein-protein interaction (PPI) enrichment among the synthetic lethal candidates scoring in two or more of the CRISPR-MEKi screens using the Metascape suite of tools (http://metascape.org; STAR Methods; Tripathi et al., 2015) . We evaluated enrichment of genes within the MSigDB canonical pathways database and observed strong representation of members of the RTK-RAS-MAPK signaling pathways (Figure 2A ). With the exception of KEAP1-mutant NCI-H2030 and NCI-H647, the other eight cell lines demonstrated strong dependence on several well-annotated RTK-RAS-MAPK pathways as well as the MTOR and CDC42 signaling pathways ( Figure 2B ).
To understand the potential PPI complexes represented among the MEKi synthetic lethal candidates, we compiled top synthetic lethal interactors from each of the screens into a single gene list and generated a single merged PPI network ( Figure 2C ). This network contains the subset of proteins that form physical interactions with at least one other member in the list, based on established interaction databases (STAR Methods). We applied the Molecular Complex Detection (MCODE) algorithm to identify densely connected network components. We observed PPI clusters involving a number of signaling pathways with most notable enrichment of interactions within several different RTK signaling components, RAS-RAF-MAPK pathway members, and CRK-related signaling partners.
We identified multiple genes encoding other MAPK pathway members recurrently scoring as potent sensitizers of MEK inhibition, including RAF1, BRAF, and MAPK1 (Figures 1J, 2D , and 2E). Examination of MEKi co-dependencies across all cell lines screened revealed a robust dependence on expression of multiple MAPK pathway signaling members, with the exception of NCI-H2030 and NCI-H647, which demonstrated more restricted dependence primarily on SHOC2 ( Figure 2D ). Notably, both of these cell lines harbor mutations in the KEAP1 gene which has been shown to confer resistance to MEK inhibition (Krall et al., 2017) . We found other classes of genes that scored as preferential dependencies including the anti-apoptotic signaling proteins BCL2L1 and MCL1, integrin-related signaling proteins, and a class of genes involved in heparan sulfate biology, including EXT1, EXT2, EXTL3, and SLC35B2 ( Figure 2D ). Specific examination of DMSO and trametinib sensitivity scores for the MAPK pathway members revealed strongly recurrent differential sensitivity to knockout of these genes in the context of trametinib, with SHOC2 being the strongest synthetic lethal candidate identified in these screens ( Figure 2E ). While all cell lines demonstrated clear dependence on SHOC2 in the presence of trametinib, we observed an apparent bimodal dependency ( Figure S2A ) in trametinib sensitivity score that may relate to modest differences in Cas9 activity across the screens ( Figure S2B ) as well as underlying transcriptomic and functional features ( Figures S2C and S2D ).
Taken together, our CRISPR-MEKi screens have identified that KRAS mutant cancer cell lines treated with the MEK1/2 CRISPR-MEKi screens. Each node represents a protein that scored in one or more CRISPR-MEKi screens and edges represent interactions derived from the BioGrid, InWeb_IM, and OmniPath databases. (D) Co-dependency plot for selected genes across the 10 CRISPR-MEKi screens. A black square indicates that the cell line is dependent on the gene with an FDR < 0.25 and a trametinib sensitivity score % À0.5. (E) Summary of differential dependence for RTK-RAS-MAPK-related genes in the context of MEK inhibition. Mean sensitivity score in DMSO (D) or trametinib (T) is shown for each gene. inhibitor trametinib demonstrate a striking sensitivity to additional loss-of-function perturbations within one or more RTK-RAS-MAPK signaling pathways. Across all ten CRISPR-MEKi screens, SHOC2 was the strongest MEKi synthetic lethal candidate; therefore, we have focused subsequent studies on validating and credentialing SHOC2 as a potential therapeutic target.
SHOC2 Suppression Specifically Cooperates with MEK Inhibition to Impair Proliferation and Survival of RAS-Driven Cancer Cells
To further investigate the preferential dependency on SHOC2 expression in the context of trametinib treatment, we performed knockdown of SHOC2 or control gene expression in PA-TU-8902 pancreatic cancer cells, an additional KRAS G12V mutant cell line that was not used for CRISPR-MEKi screening. Using a doxycycline-regulatable short-hairpin RNA (shRNA), we achieved robust suppression of SHOC2 and potent sensitization to trametinib treatment compared with control DMSO treatment in both short-and long-term proliferation assays (Figures 3A-3C and S3A-S3D). In complementary experiments, we created single-cell clones (SCCs) that harbor SHOC2 knockout and complete loss of SHOC2 protein expression using CRISPR-Cas9 genome editing ( Figures 3D and S3E ). SHOC2 knockout (KO) SSCs demonstrated profound sensitivity to trametinib relative to the DMSO treatment condition ( Figures 3E, 3F , and S3F-S3H). The proliferation and survival of SHOC2 SCCs was unimpaired at baseline, without trametinib treatment. To confirm that trametinib sensitization is a direct consequence of SHOC2 KO in these SCCs, we performed a rescue experiment whereby a SHOC2 cDNA was exogenously expressed in two different SCCs (Figures 3G-3I and S3I). Overexpression of SHOC2 restored the trametinib responsiveness of the PA-TU-8902 SCCs to that of the parental cell line, thus completely eliminating the sensitizing effect of SHOC2 KO. Lastly, using an in-cell western assay, we determined that loss of SHOC2 reduced the half maximal inhibitory concentration (IC 50 ) for inhibition of phospho-ERK1/2 (p-ERK) levels by trametinib in SHOC2 KO SCCs of PA-TU-8902 and MIA PaCa-2 (Figures 3J, 3K, and S3J).
Using the doxycycline inducible shRNA system, we further validated that SHOC2 knockdown sensitized the KRAS G12A mutant NCI-H2009 non-small cell lung cancer line to trametinib ( Figures 4A and S4A ). We also observed that SHOC2 knockdown conferred sensitivity to other allosteric MEK1/2-inhibitors, including Selumetinib and the dual-mechanism MEKi CH5126766, which also prevents MEK phosphorylation by RAF ( Figure 4A ) (Ishii et al., 2013; Samatar and Poulikakos, 2014) . In contrast, SHOC2 suppression failed to confer substantial sensitivity to treatment with a paradox-breaker BRAF inhibitor (PLX7904), an ATP-competitive BRAF inhibitor (Vemurafenib), or a pan-RAF inhibitor (LY3009120) (Figures 4A, S4E, and S4F). We detected very mild but less consistent sensi-tization to ERK inhibition upon SHOC2 suppression with variability observed between cell lines (NCI-H2009 and PA-TU-8902), different shRNA constructs, and three different ERK1/2 inhibitors (GDC-0994, SCH772984, and BVD523) ( Figures 4A,  S4E , and S4F). SHOC2 suppression did not sensitize to chemotherapy treatment with Gemcitabine ( Figure 4A ) and conferred no further sensitization of the KRAS G12C mutant cancer cell line MIA PaCa-2 to a KRAS G12C -specific inhibitor (Janes et al., 2018) ( Figure S4G ). These observations demonstrate that SHOC2 acts as a potent synthetic lethal partner, specifically with MEKi.
We next examined whether suppression of SHOC2 expression conferred sensitivity to trametinib in cancer cell lines with other oncogenic drivers. SHOC2 knockdown conferred modest trametinib sensitivity to the EGFR L858R/T790M mutant or NRAS Q61K mutant cancer cells but not to a BRAF V600E mutant cancer cell line ( Figures 4B-4D and S4B-S4D). SHOC2 knockdown also sensitized the EGFR-and NRAS mutant lines to Selumetinib but not to Gemcitabine ( Figures 4C and 4D ). Furthermore, we observed similar sensitization of SHOC2 suppression to MEK inhibition in MET-amplified and ERBB4 mutant lung cancer cell lines (data not shown). These observations demonstrate that suppression of SHOC2 cooperates with MEKi across a range of RAS-driven cancer cell contexts.
SHOC2 Suppression Cooperates with MEKi to Inhibit
Proliferation in Three-Dimensional Culture and Impair In Vivo Tumorigenesis We found that RAS-driven pancreatic and lung cancer cell lines do not require SHOC2 expression for growth under standard two-dimensional adherent culture conditions in the absence of MEKi treatment. However, Wang et al. reported that SHOC2 was essential for the baseline proliferation and survival of nonadherent NRAS-or KRAS mutant leukemia cell lines (Wang et al., 2017b) . We investigated whether SHOC2 suppression or KO impairs baseline growth and MEKi sensitivity in the KRAS G12V mutant PA-TU-8902 pancreatic cancer cell line grown in three-dimensional culture conditions. Short-term assays in ultra-low attachment conditions (Rotem et al., 2015) revealed that SHOC2 suppression in PA-TU-8902 cells led to an approximately 28% reduction in proliferation (average of SHOC2 sh1 and sh2) compared with control cells ( Figure 5A ). We observed a modest additive effect of trametinib treatment with concurrent SHOC2 suppression. Similarly, the PA-TU-8902 SHOC2 KO clones grown in three-dimensional organoid culture conditions demonstrated a mild baseline effect but a modest enhancement of trametinib sensitivity compared to controls ( Figure 5B ).
We next investigated whether SHOC2 KO cooperated with trametinib treatment in vivo using an immunocompromised mouse xenograft model. We implanted SHOC2 KO or control cells subcutaneously into immunodeficient mice and observed potent trametinib sensitization of both SHOC2 KO and MAPK1 KO control cells in comparison to cells harboring a negative control sgRNA ( Figures 5C-5F ). We noted that SHOC2 KO decreased average tumor growth in the absence of MEKi by 44% (p = 0.0015). However, the combination of SHOC2 KO and trametinib treatment led to complete impairment of subcu-taneous tumor progression in this model. To investigate the levels of p-ERK in the PA-TU-8902 SHOC2 KO or control tumors, we harvested tissue from two treated tumors after the fourth dose of trametinib (1 mg/kg) or vehicle treatment at approximately 20 days post-implantation and observed that 6B). To infer functional dependence on these RTKs, we evaluated the differential sensitivity scores for the top-four activated RTKs upon trametinib treatment for each respective cell line. We found that most of the activated RTKs that we observed, such as MET/HGFR, HER3, IR, and IGF-IR, demonstrated correspondingly negative differential sensitivity scores for the cell lines in which they are activated ( Figure 6C ). We observed strong upregulation of the MET/HGFR activity in PA-TU-8902 after 48 h of trametinib treatment, as assessed by RTK array ( Figures  6A and 6B) , and we confirmed this finding by immunoblotting for activated p-MET in PA-TU-8902 cells following trametinib addition ( Figure 6D) .
Given that SHOC2 is a positive regulator of RAF1-mediated MAPK signaling, we investigated the impact of SHOC2 suppression on MAPK pathway reactivation upon MEK inhibition. We examined the kinetics of p-ERK suppression and reactivation after trametinib treatment and found robust reactivation of p-ERK levels out to 96 h after trametinib treatment in control cells compared to markedly reduced p-ERK reactivation in SHOC2 knockdown cells ( Figures 6E and 6F ). We did not observe a substantial difference in levels of p-AKT Ser473 in SHOC2 KO or control cells. We further confirmed this reduction of p-ERK levels in SHOC2 KO cells upon trametinib treatment and also demonstrated that exogenous expression of a SHOC2 cDNA restores p-ERK levels to the baseline post-treatment levels seen in the parental-cell-line control (Figures 6G and 6H ). To extend these findings, we suppressed SHOC2 with small interfering RNAs (siRNAs) in additional lines A549, NCI-H23, MIA PaCa-2, and NCI-H2009 ( Figure S6 ). Although we observed a variable range of p-ERK reduction at baseline upon SHOC2 loss across cell lines, we found SHOC2 loss conferred a consistent blunting of p-ERK reactivation in response to trametinib ( Figures S6A  and S6B ).
To further investigate the possible connection between growth-factor-mediated-RTK activation of RAS-RAF-MAPK signaling through SHOC2, we serum starved PA-TU-8902 cells with SHOC2 targeting or control shRNAs, and then performed a time course analysis after pulsing cells with fetal bovine serum (FBS), a rich source of growth factor ligands to activate multiple RTK signaling pathways ( Figures 6I and 6J) . In control cells, we observed a rapid and robust reactivation of p-ERK upon addition of FBS that was significantly blunted in SHOC2-suppressed cells ( Figures 6I and 6J) . Moreover, we observed a similar reduction of p-ERK levels in PA-TU-8902 SHOC2 KO cells that have been serum starved and pulsed with HGF, the ligand for the MET receptor ( Figures 6K-6M ).
Evaluation of differential sensitivity scores from the CRISPR-MEKi screens revealed that SHOC2 exhibits strong positive correlations with various members of the RTK signaling pathway, including PTPN11, GRB2, SOS1, KRAS, BRAF1, and RAF1 ( Figures S7A-S7G ). To further investigate the relationship to PTPN11/SHP2 dependency, we compared the impact of SHOC2 knockdown to that of SHP2 inhibition with SHP099 on differential trametinib sensitivity in KRAS mutant cells A549 and NCI-H2030, as well as an expanded panel of cell lines, including breast and colorectal carcinoma cell lines ( Figure S7H ). We found a striking correlation between the degree of sensitization mediated by SHOC2 knockdown and SHP099 sensitivity during co-treatment with trametinib, sug-gesting parallel functional roles for SHP2 and SHOC2 in mediating RKT-feedback signaling in response to trametinib. We conclude that RTK activation plays a key role in upstream signaling to reactivate p-ERK in response to MEK inhibition whereby SHOC2 functions as a central node to facilitate RAF-MAPK pathway reactivation.
Acute Proteasomal Degradation of SHOC2 in Combination with Trametinib Potently Suppresses MAPK Signaling and Proliferation in KRAS Mutant Cancer Cells
The SHOC2 protein does not contain enzymatic domains that would be targetable by conventional small molecule inhibitors. However, we hypothesized that SHOC2 may be amenable to ligand-mediated protein degradation as a potential therapeutic strategy. We modeled this therapeutic approach with SHOC2 by utilizing the dTAG system, a chemical biology system that leverages cell-permeable heterobifunctional degraders to study the consequences of target protein degradation (Nabet et al., 2018) . In this system, treatment of cells expressing a target protein fused to FKBP12 F36V with the degrader small molecule dTAG-13 causes rapid CRBN E3 ligase-mediated ubiquitination and proteasomal degradation of the protein with high specificity (Nabet et al., 2018) (Figure 7A ). We generated a SHOC2 expression construct with an amino-terminal FKBP12 F36V tag (FKBP12 F36V -SHOC2) and stably expressed this gene in PA-TU-8902 and MIA PaCa-2 SHOC2 KO SCCs.
To determine the effect of acute SHOC2 loss in the context of MEKi treatment and adaptive reactivation of p-ERK, we pretreated PA-TU-8902 and MIA PaCa-2 FKBP12 F36V -SHOC2 cells with trametinib for 24 h ( Figure 7B ) followed by treatment with dTAG13 compound for 48 h. We observed robust loss of p-ERK at 1 h post-trametinib treatment and rebound of p-ERK within 24 h. Subsequent dTAG13 compound addition led to the full loss of SHOC2 protein within 30-60 min. Concurrently, we observed a reduction in p-MEK and p-ERK following SHOC2 degradation in the presence of trametinib. SHOC2 has been shown to mediate dephosphorylation of the inhibitory (L) PA-TU-8902 parental cells (P), SHOC2 single-cell KO clones (SCC1 and SCC2), and SCC1/2 overexpressing SHOC2-V5 treated with rhHGF (10 ng/mL) for 1 h. (M) Relative densitometry quantification of p-ERK/ERK levels normalized to trametinib-treated PA-TU-8902 parental cells (P). For all experiments, data are represented as the mean of three or more independent biological replicates ± SEM, and statistics were derived via two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001. phosphorylation site S259 on RAF1 (Rodriguez-Viciana et al., 2006) . We found that acute loss of SHOC2 in the presence of trametinib resulted in a modest increase in RAF1 p-S259 levels in both PA-TU-8902 (18%) and MIA PaCa-2 (56%) at 48 h post-dTAG13 treatment ( Figure 7B) . Finally, to model a SHOC2 degrader therapeutic strategy and to test the functional impact of acute SHOC2 degradation on cell viability, we treated PA-TU-8902 and MIA PaCa-2 SHOC2 KO SCCs expressing either SHOC2-V5 or FKBP12 F36V -SHOC2 with trametinib, dTAG13, or in combination ( Figure 7C) . While SHOC2 KO cells demonstrated profound sensitivity to trametinib treatment relative to DMSO, the restoration of SHOC2 expression by FKBP12 F36V -SHOC2 imparted an equivalent degree of rescue in viability as SHOC2-V5 expression. Upon treatment with dTAG13 (leading to SHOC2 degradation) in combination with trametinib, we observed a strong and selective sensitization of FKBP12 F36V -SHOC2 cells to trametinib treatment. Taken together, our results provide proof of concept for a SHOC2 degrader strategy as a potential therapeutic approach.
DISCUSSION
Employing first genome-scale and then secondary-focused CRISPR-Cas9 screening libraries, we have defined a comprehensive landscape of synthetic lethal interactions with MEK inhibition. We identified several classes of synthetic lethal interactors that scored recurrently in our CRISPR-MEKi screens, including genes encoding other MAPK pathway members, anti-apoptotic signaling proteins, integrin-related signaling partners, and proteins involved in heparan sulfate biology. In aggregate, these data provide a compendium of possible targets highlighting potential therapeutic opportunities for vertical inhibition of the MAPK signaling pathway as well as disruption of orthogonal signaling pathways to enhance MEK inhibitor efficacy.
We identified recurrent co-dependencies with MEKi, such as SHOC2, RAF1, MAPK1, and PTPN11. We also found remarkable heterogeneity for other strong modifiers of MEKi sensitivity, including numerous pharmacologically tractable synthetic lethal targets that scored as potent sensitizers to trametinib in only a subset of lines, such as BCL2L1, MCL1, MTOR, PTK2, and FGFR1. While the cell lines subjected to genome-scale screens within our study all harbor KRAS mutations, they differ in numerous other ways that could drive biologic differences and context specificity, including differing lineage (2 lung, 1 pancreas) and genetic features (Table S1 ). The heterogeneous nature of such functional dependencies highlights the key challenge of proper patient selection for therapeutic strategies. Without identifiable genomic biomarkers for most of these dependencies, our observations also suggest the potential of functional profiling (genetic, pharmacologic, or other) of patient-derived samples to identify specific cancer cell dependencies for the design of combination therapy regimens.
Most notably, we demonstrate that multiple additional perturbations to the RTK-RAS-MAPK pathway strongly cooperated with MEKi to inhibit proliferation and survival of RASdriven cancer cells. Certain members of the MAPK pathway that scored in our CRISPR-MEKi screens, such as RAF1, BRAF, or MAPK1, likely reflect the added effect of further vertical suppression of the RAF-MEK-ERK signaling cascade in the context of partial inhibition of the pathway with trametinib. However, another class of targets clearly reflect disruption of upstream RTK-mediated signaling, including MET, FGFR1, GRB2, SOS, PTPN11, and SHOC2. Indeed, an integrative meta-analysis of signaling pathways enriched in all recurrent scoring synthetic lethal candidates further highlighted the strong representation of the RTK-RAS-MAPK pathway in the CRISPR-MEKi screening data (Figure 2) . Moreover, RTK reactivation has been shown to be a mechanism of resistance to RAS-MAPK pathway inhibition in several contexts, with RTKs such as EGFR (Corcoran et al., 2012; Prahallad et al., 2015) , ERBB3 (Kitai et al., 2016; Sun et al., 2014) , FGFRs (Kitai et al., 2016; Lee et al., 2014; Manchado et al., 2016) , and others (Ahmed et al., 2019; Ruess et al., 2018) playing major roles. Therefore, these findings support the hypothesis that compensatory signaling through RTK-RAS-MAPK pathways is essential for survival in the context of trametinib treatment.
We identified SHOC2 as the most recurrent and strongest synthetic lethal target with MEKi in KRAS mutant lung and pancreatic cancer cell lines. Additionally, disruption of SHOC2 sensitizes other RAS-driven cancer cell contexts to MEK inhibition, including EGFR-and NRAS mutant lung cancers, but not BRAF mutant lung cancer. KO or suppression of SHOC2 expression was found to potently cooperate most specifically with MEK inhibition; yet, we observed a mild, less consistent sensitization to ERK inhibitor treatment. However, SHOC2 loss had no significant impact on dose response curves with a KRAS G12C inhibitor, a range of RAF inhibitors (ATP-competitive BRAF, paradoxbreaker BRAF, and pan-RAF), or chemotherapy treatment. During the revision of our manuscript, Jones et al. demonstrated SHOC2 is required for RAF dimerization induced by MEK inhibition , and in corroboration with our findings, they reported that the loss of SHOC2 confers a selectively potent sensitization of KRAS mutant lung cancer cells to MEKi. RAF inhibition has been previously shown to promote RAF dimerization (Hatzivassiliou et al., 2010; Jin et al., 2017; Peng et al., 2015) , and this was not inhibited by SHOC2 loss . ERK inhibition has also been shown to promote RAF dimerization that is SHOC2 dependent . However, p-ERK levels were unaffected by SHOC2 loss in the context of ERK inhibition . Additional biochemical studies of RAS-MAPK pathway signaling flux in the context of pathway inhibition will be necessary to fully understand the differential impact of SHOC2 loss in the context of MEK inhibition as compared to RAF or ERK inhibition.
SHOC2 has been reported to bind exclusively with MRAS and directly with the PP1c leading to dephosphorylation of c-RAF at S259 and consequent MAPK pathway activation (Rodriguez-Viciana et al., 2006; Simanshu et al., 2017) . The ternary complex formed by MRAS, SHOC2, and PP1c mediates c-RAF activation through dephosphorylation at the negative regulatory site S259, leading to subsequent displacement of 14-3-3 and increased membrane localization (Rodriguez-Viciana et al., 2006; Simanshu et al., 2017; Young and Rodriguez-Viciana, 2018) . This membrane localization promotes c-RAF dimerization and activation of the RAS-RAF-MAPK signaling pathway. Indeed, we found a modest increase in p-S259 c-RAF following acute SHOC2 loss in the presence of trametinib. These findings corroborate those of Jones and colleagues, who similarly found that the loss of SHOC2 leads to an increase in the inhibitory ''p-S259'' site of RAF1 and the equivalent site of BRAF in response to trametinib treatment, preventing RAF dimerization and downstream signaling to reactivate ERK1/2 . MRAS itself is a weak activator of MAPK signaling (Kimmelman et al., 2002; Young and Rodriguez-Viciana, 2018) , and in our genome-scale screens, we did not observe MRAS as a synthetic lethal partner with MEKi. Furthermore, unlike other pathway members of the RTK signaling pathway, the gene essentiality profile of MRAS failed to correlate with SHOC2 (data not shown). These observations suggest that SHOC2 may function outside of the Noonanlike-syndrome-associated MRAS/SHOC2/PP1C ternary complex in the context of MEKi treatment of KRAS mutant cancers. Li and colleagues had previously found that SHOC2 interacts with KRAS, HRAS, and NRAS G12V mutants with a high degree of specificity (Li et al., 2000) ; however, uncertainty remains regarding the interactions of SHOC2 and other RAS isoforms. Taken together, further studies are warranted to evaluate the specific RAS/SHOC2 complex that is involved in MEKi sensitivity of mutant KRAS cells.
Our observations suggest a critical role for SHOC2 in mediating the proliferation and survival of RAS-driven cancer cells in the context of MEK inhibition. We demonstrate that multiple heterogeneous RTKs are consistently activated in response to MEK inhibition across multiple KRAS mutant cancer cell lines and that SHOC2 depletion blunts the reactivation of MAPK signaling observed in control cells. Most of these RTKs showed modest synthetic lethal interactions within the screens of corresponding cell lines ( Figure 6 ). The phenomenon of cancer cells exhibiting compensatory upregulation of multiple RTKs in response to MAPK inhibition motivated the rationale in targeting SHP2, a ubiquitous node downstream of multiple RTK signaling pathways, in combination with various MAPK inhibitors to prevent RTK-mediated adaptive resistance (Fedele et al., 2018; Mainardi et al., 2018; Nichols et al., 2018; Ruess et al., 2018) . Indeed, we found parallel function of SHOC2 to be a central node in RTK signaling, as determined by strong positive correlation in gene essentiality profiles of SHOC2 and PTPN11 within our screens, as well as strongly correlated effects of SHP2 inhibitor treatment and SHOC2 loss in combination with MEKi treatment across an expanded panel of cell lines. SHOC2 may offer an additional therapeutic target as a critical node mediating feedback reactivation of p-ERK signaling.
Intriguingly, we found that depletion of SHOC2 had no effect on baseline proliferation in two-dimensional culture. In three-dimensional, non-adherent culture conditions, as well as in an in vivo subcutaneous xenograft model, we observed a modest dependency on SHOC2 in the absence of MEKi treatment, consistent with recent CRISPR-Cas9 screening data that showed SHOC2 is essential for proliferation of non-adherent RAS mutant leukemia lines (Wang et al., 2017b) . These findings suggest that mechanisms of RAS-RAF-MAPK activation differ between two-and three-dimensional growth culture conditions. Indeed, recent studies that examined the consequences of pharmacologic inhibition of KRAS G12C in lung cancer models demonstrated that RAS-pathway dependency appears to be more pronounced in three-dimensional culture compared with twodimensional culture (Janes et al., 2018) . In a recent study that was published during the review of this paper, Boned del Rio et al. describe a SHOC2-independent mechanism of sustained p-ERK activation mediated by internalization of palmitoylated H/NRAS and cRAF that requires FAK/PAK-mediated phosphorylation and activation of cRAF (Boned Del Río et al., 2019) . Our CRISPR-MEKi screens conducted in two-dimensional culture demonstrate multiple integrins and integrin-related signaling pathway members as synthetic lethal candidates, including IT-GAV, ITGB1, CRKL, and RAC1. We surmise that the loss of integrin-mediated ERK phosphorylation in three-dimensional growth conditions may result in a preferential dependence on SHOC2mediated ERK activation for sustained ERK signaling and survival. Furthermore, the interaction of SHOC2 and SCRIB may coordinate regulation of RAC1 signaling and other cell polarity pathways to impact ERK signaling (Young et al., 2013) . Thus, integrin-related signaling may play a fundamental role in coordinating RAS-pathway activation independent of SHOC2, thus allowing SHOC2 to be dispensable in two-dimensional growth but dependent in three-dimensional culture conditions. The SHOC2 protein is composed almost entirely of leucinerich repeats and appears to be a challenging target for small molecule development. However, the ternary complex composed of MRAS, SHOC2, and PP1c plays a fundamental role in the dephosphorylation of S259 on RAF1, raising the possibility for development of small molecules that target novel ligand pockets in SHOC2 within this enzymatic complex. Achievement of small molecules that bind SHOC2 could enable ligand-mediated protein degradation approaches for therapeutic development (Lu et al., 2014; Olson et al., 2018; Winter et al., 2015) . In proof-of-concept experiments using the dTAG system to model acute degradation of SHOC2 (Figure 7) , we demonstrated the feasibility of small-molecule-mediated proteasomal degradation of the SHOC2 protein. Moreover, this approach blunted p-ERK reactivation and potently decreased the viability of KRAS mutant cells in the context of trametinib treatment. These data provide a compelling basis for future therapeutic efforts in developing degrader compounds that directly bind the SHOC2 protein and target it for degradation in combination with MEKi. While PP1c has numerous cellular targets, the specific PP1c conformation within the complex of MRAS and SHOC2 may also provide unique opportunities for targeting its RAF activation function (Rodriguez-Viciana et al., 2006) . Further structural study of SHOC2 alone and within the MRAS: SHOC2:PP1 ternary complex will undoubtedly inform therapeutic development efforts.
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METHODS DETAILS Trametinib Titration for CRISPR-Cas9 Screens
The doses of trametinib to use in these screens were determined by propagating cells in different concentrations of trametinib to determine the effect on cell proliferation. In parallel, the level of phospho-ERK depletion in cells treated with different concentrations of trametinib was determined. For the proliferation assay, 1.5 3 10e6 cells were seeded in 10 cm plates and cells were immediately treated with different concentrations of trametinib. Cells were passaged every 4 days, and cells were counted at each passage. Protein samples were harvested at each count and phospho-ERK levels were assessed by immunoblot analysis.
Determination of Infection Conditions for CRISPR Pooled Screens
Optimal infection conditions were determined in each cell line in order to achieve 30%-50% infection efficiency, corresponding to a multiplicity of infection (MOI) of $0.5 -1. Spin-infections were performed in 12-well plate format with 3 3 10e6 cells per well. Optimal conditions were determined by infecting cells with different virus volumes (0, 25, 50, 75, 150, 300 uL for NCI-H23 and 0, 25, 75, 150, 300, 500 uL for A549) with a final concentration of 4 ug/mL polybrene. Cells were spun for 2 hours at 930 g at 30 C. Approximately 24 hours after infection, cells were trypsinized and 1.5 3 10e5 cells from each infection were seeded in 2 wells of a 6-well plate, each with complete medium, one supplemented with the appropriate concentration of puromycin. Cells were counted 3 days post selection to determine the infection efficiency, comparing survival with and without puromycin selection. Volumes of virus that yielded $30%-50% infection efficiency were used for screening.
Genome Scale CRISPR Resistance Screens
The Avana-4 barcoded sgRNA library contains 74,687 sgRNA, which includes an average of 4 guides per gene and 1000 non -targeting control guides (Doench et al., 2014) . Screening-scale infections were performed with the pre-determined volume of virus in the same 12-well format as the viral titration described above and infected wells were pooled 24 hr post-centrifugation. Infections were performed with at least 1.1 3 10e8 cells per replicate, in order to achieve a representation of at least 500 cells per sgRNA following puromycin selection ($4 3 10E7 surviving cells). Approximately 24 hours after infection, all wells within a replicate were pooled and split into T225 flasks. Puromycin was added to remove uninfected cells and selection maintained for 4 days. After a 48-hour washout of puromycin, 4 3 10e7 cells were seeded in 2-Stack culture chambers (Corning #3269) in media with 10 nM trametinib or DMSO control on day 7 post-infection. Cells were passaged in fresh media containing drugs every 3-4 days. Cells were harvested 14 days after initiation of treatment. For all screens, genomic DNA (gDNA) was isolated using Maxi (3 3 10e7-1 3 10e8 cells) kits according to the manufacturer's protocol (QIAGEN). PCR and sequencing were performed as previously described (Doench et al., 2016; Piccioni et al., 2018) . Samples were sequenced on a HiSeq2000 (Illumina). For analysis, the read counts were normalized to reads per million and then log 2 transformed. The log 2 fold-change of each sgRNA was determined relative to the initial time point for each biological replicate.
Secondary Focused Library and CRISPR-Cas9 Screens
The secondary screening sgRNA library was prepared as previously described (Doench et al., 2016) . Top scoring genes with a Differential Sensitivity Score (trametinib versus DMSO control) having a rank score of 3 or higher by the STARS algorithm (Doench et al., 2016) were chosen from among the three genome-scale CRISPR-MEKi screens described here as well as a fourth previously published CRISPR-MEKi screen in the PA-TU-8988T cell line (Wang et al., 2017a) (Table S3 ). For library construction, we utilized the pXPR-BRD003 all-in-one vector expressing CAS9 and a single sgRNA targeting a gene of interest (Doench et al., 2016) . In total, this library contained sgRNAs targeting 527 experimental genes and 116 positive control cell essential genes, with six sgRNAs per gene. Additionally, we included 1083 non-targeting and non-genic targeting sgRNAs. The total number of sgRNAs in the library was 4831. trametinib dose was determined in the same way as the genome-scale screens. The infection and screening protocols were similar to the genome-scale screen; cells were treated with puromycin 24 hours post-infection and remained under puromycin selection for 6 days before adding trametinib or DMSO. Screens were conducted with a representation of 1000 cells/sgRNA.
Analysis of Genome Scale and Secondary Focused CRISPR-MEKi Screens
For genome-scale screens, the log2(fold-change) (LFC) in sgRNA representation was calculated between the 14-day treatment endpoint for cells treated with trametinib or DMSO control and the initial pool of sgRNAs plasmid used to generate virus. For focused secondary screens, the LFC was calculated using the 14-day treatment endpoint and an early time point 7 days post-infection and immediately prior to initiation of treatment. To identify genes whose depletion modified the response to MEKi, we averaged the measured abundance of guides targeting each gene to calculate gene-level scores. Specifically, we calculated a ''Trametinib Sensitivity Score'' and a ''DMSO Sensitivity Score'' reflecting the mean log2-fold change between the endpoint (14 days in trametinib or control) and an early time point (immediately post-selection) for all sgRNAs targeting each gene in the trametinib and control arms of the screen, respectively (STAR Methods). We then compared the trametinib-treated arm with the control DMSO-treated arm of each screen to yield a ''Differential Sensitivity Score,'' reflecting the preferential dependence of each gene in the presence of trametinib. We prioritized candidates that showed enhanced depletion in the context of MEK inhibition and were also strongly depleted in the trametinib arm of the screen, thus displaying highly negative Differential Sensitivity Scores and Trametinib Sensitivity Scores. STARS analysis v1.3 was performed in order to collapse guide-level data to genes. STARS analysis was performed as previously described (Doench et al., 2016) . The code for STARS analysis is written in Python, and is available on the Broad Institute's website: http://www.broadinstitute.org/rnai/public/software/index.
Meta-analysis of CRISPR-MEKi Screening Data
We used the Metascape suite of tools to perform a meta-analysis of pathway and protein-protein interaction (PPI) enrichment among these synthetic lethal candidates scoring in two or more of the CRISPR-MEKi screens. Metascape is a publicly available web-based pathway enrichment and clustering algorithm (http://metascape.org; STAR Methods) (Tripathi et al., 2015) . Genes were included in the analysis if they scored in one or more screens with a Differential Sensitivity Score having an FDR % 0.25 by the STARS algorithm and a Trametinib Sensitivity Score of % À0.5 or R 0.5 for the negative selection (MEKi sensitizer) or positive selection (MEKi resistance) analyses, respectively. To specifically interrogate known signaling pathways represented within the MEKi modifier screen data, we focused the enrichment analysis on the MSigDB Canonical Pathways database. For each given gene list, protein-protein interaction enrichment analysis was conducted with the BioGrid, InWeb_IM and OmniPath databases per the standard metascape algorithm. The resultant networks contain the subset of proteins that form physical interactions with at least one other member in the list. If the network contains between 3 and 500 proteins, the Molecular Complex Detection (MCODE) algorithm (Bader and Hogue, 2003) was been applied to identify densely connected network components. The network displays and integrated data representations for each figure were derived from standard plots generated by the Metascape software.
Generation of Expression Constructs
Wobble mutants were introduced into SHOC2 ORF (SHOC2 transcript NM007373.3) to allow for SHOC2 protein expression in the presence of SHOC2 sgRNAs. Both the NGG PAM sequence and the first amino acid in the guide sequence were mutated using the QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies, 210515). Original ORF sequence, mutated sequences, and FKBP12 F36V tagged sequences are below. Type SHOC2 ORF cDNA  ATGAGTAGTAGTTTAGGAAAAGAAAAAGACTCTAAAGAAAAAGATCCCAAAGTACCATCAGCCAAGGAAAGAGAAAAGGAGGCAAA  AGCCTCTGGAGGTTTTGGGAAAGAGAGCAAAGAAAAAGAACCTAAGACCAAAGGGAAAGATGCCAAAGATGGAAAGAAGGACTC  CAGTGCTGCCCAACCAGGGGTGGCATTTTCAGTTGACAATACGATCAAACGGCCAAACCCAGCACCTGGGACTAGAAAAAAATC  CAGCAATGCAGAGGTGATTAAAGAGCTCAACAAATGCCGGGAAGAGAATTCAATGCGTTTGGACTTATCCAAGAGATCTATACACA  TATTGCCATCATCAATCAAAGAGTTGACTCAATTAACAGAACTTTATTTATACAGTAACAAATTGCAGTCCCTCCCAGCAGAGGTGG  GATGTTTAGTAAATCTCATGACACTGGCTCTAAGTGAAAATTCACTTACCAGTTTGCCTGACTCTCTTGATAACTTGAAGAAGCTGC  GGATGCTTGATTTACGGCATAATAAACTGAGAGAAATTCCTTCAGTGGTGTATAGGCTGGATTCTCTCACCACTCTTTACCTTCGCT  TTAATCGTATAACTACTGTGGAAAAGGACATCAAAAACTTGTCAAAACTCAGCATGCTTAGCATTCGAGAGAACAAAATTAAACAAC  TACCTGCTGAAATTGGTGAATTATGTAACCTCATTACGCTGGATGTAGCTCACAATCAACTTGAACACCTTCCAAAGGAGATTGGA  AACTGTACACAGATAACCAACCTTGACTTGCAGCACAATGAACTGCTAGACCTCCCAGATACTATAGGAAACCTGTCCAGTTTAAG  TCGTCTTGGTCTGAGATATAACAGACTGTCAGCAATACCCAGATCATTAGCAAAATGCAGTGCACTTGAAGAATTAAATTTAGAGAA  CAATAACATTTCTACTTTACCAGAGAGTCTTTTATCAAGTCTTGTGAAACTGAATAGTTTGACCTTAGCTAGAAATTGCTTCCAGTTGT  ATCCAGTGGGTGGTCCATCTCAGTTTTCTACCATCTATTCCCTCAACATGGAACACAATCGAATCAACAAAATTCCATTTGGAATTTT  CTCCAGAGCAAAAGTATTAAGTAAGCTGAATATGAAGGACAATCAGTTAACATCACTTCCCTTGGATTTTGGAACTTGGACCAGTAT  GGTAGAATTGAATTTAGCCACTAATCAGCTCACAAAGATCCCTGAGGATGTGTCTGGTCTCGTTTCTCTTGAGGTTCTTATCTTATC  AAACAATCTTCTAAAGAAGCTTCCCCATGGTCTTGGAAACCTTAGGAAGTTAAGAGAGTTGGATCTAGAAGAGAACAAATTGGAATC  CTTGCCAAATGAAATTGCATATCTTAAGGATTTACAGAAATTAGTCTTGACAAACAACCAGTTGACCACTCTTCCCAGAGGCATTGG  TCACCTTACTAATCTCACACATCTGGGCCTTGGAGAGAACCTACTTACTCACCTTCCTGAAGAAATTGGTACACTGGAGAACCTAG  AAGAACTGTATTTGAATGACAACCCCAACCTGCATAGCCTTCCCTTTGAGCTGGCACTCTGCAGCAAGCTTTCAATCATGAGTATT  GAGAACTGTCCACTCAGTCACCTTCCACCTCAGATTGTTGCTGGGGGGCCTTCTTTCATCATTCAGTTCTTAAAGATGCAGGGTCC  ATATCGTGCCATGGTC Mutagenized SHOC2 ORF: Guides 2 and 3 (Used to Make PA-TU-8902 Cell Lines SCC1, SCC2 and SSC3) ATGAGTAGTAGTTTAGGAAAAGAAAAAGACTCTAAAGAAAAAGATCCCAAAGTACCATCAGCCAAGGAAAGAGAAAAGGAGGCAAA AGCCTCTGGAGGTTTTGGGAAAGAGAGCAAAGAAAAAGAACCTAAGACCAAAGGGAAAGATGCCAAAGATGGAAAGAAGGACTC CAGTGCTGCCCAACCAGGGGTGGCATTTTCAGTTGACAATACGATCAAACGGCCAAACCCAGCACCTGGGACTAGAAAAAAATC CAGCAATGCAGAGGTGATTAAAGAGCTCAACAAATGCCGGGAAGAGAATTCAATGCGTTTGGACTTATCCAAGAGATCTATACACA TATTGCCATCATCAATCAAAGAGTTGACTCAATTAACAGAACTTTATTTATACAGTAACAAATTGCAGTCCCTCCCAGCAGAGGTGG GATGTTTAGTAAATCTCATGACACTGGCTCTAAGTGAAAATTCACTTACCAGTTTGCCTGACTCTCTTGATAACTTGAAGAAGCTGC GGATGCTTGATTTACGGCATAATAAACTGAGAGAAATTCCTTCAGTGGTGTATAGGCTGGATTCTCTCACCACTCTTTATCTTCGAT TTAATCGTATAACTACTGTGGAAAAGGACATCAAAAACTTGTCAAAACTCAGCATGCTTAGCATTCGAGAGAACAAAATTAAACAAC
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